← Back to Clinical Trials
Recruiting NCT07543029

NCT07543029 Kangaroo Care: Breastfeeding Success and Maternal Role

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07543029
Status Recruiting
Phase
Sponsor Recep Tayyip Erdogan University
Condition Breastfeeding
Study Type INTERVENTIONAL
Enrollment 112 participants
Start Date 2025-06-01
Primary Completion 2026-06-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 49 Years
Study Type INTERVENTIONAL
Interventions
Kangaroo Mother Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 112 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Purpose: This is a randomized controlled trial designed to investigate the effects of Kangaroo Mother Care (KMC) applied in the early postpartum period to primiparous mothers on breastfeeding success and the perception of the maternal role. Methodology and Sample: Setting and Period: The study will be conducted at the Bucak State Hospital Delivery Unit between June 2025 and June 2026. Sample Size: Based on G\*Power analysis (alpha=0.05, power=80%, effect size d=0.566), a total of 112 mothers (56 intervention, 56 control) will be included, accounting for a 10% potential attrition rate. Participants will be assigned to groups using the sealed envelope method and randomization via www.random.org. Intervention: Experimental Group: Following routine care, the newborn will be placed in a "chest-to-chest" position on the mother's bare chest for Kangaroo Care. Intermittent KMC will be maintained for 24 hours, during which breastfeeding attempts will be supported. Control Group: Mothers and newborns will receive only the hospital's routine care (standard skin-to-skin contact and breastfeeding support). Data Collection Tools: Personal Information Form, Semantic Differential Scale-Myself as a Mother (to measure maternal role perception), LATCH Breastfeeding Assessment Tool (to evaluate breastfeeding success).

Eligibility Criteria

Inclusion Criteria: * For mothers: * It must be the mother's first birth, * Birth must have been vaginal, * The mother must be healthy, * The mother must voluntarily participate in the study, * The mother must not have any communication-impairing conditions (language, cognitive problems, etc.), For babies: * Birth weight must be between 2500-4000 grams; * The newborn must be healthy, * Exclusively breastfed, * The newborn must be at term gestation (38-42 weeks), * The newborn's Apgar score at 1 and 5 minutes must be above 7, * The newborn must not have any health problems that could affect breastfeeding (cleft palate, cleft lip, esophageal atresia, etc.). Exclusion Criteria: \-

Contact & Investigator

Central Contact

Gamzegül ALTAY, Assistant Professor

✉ gamzegul.altay@erdogan.edu.tr

📞 +90 464 2141059

Principal Investigator

Gamzegül ALTAY, PhD

PRINCIPAL INVESTIGATOR

Recep Tayyip Erdogan University

Frequently Asked Questions

Who can join the NCT07543029 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 49 Years, studying Breastfeeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07543029 currently recruiting?

Yes, NCT07543029 is actively recruiting participants. Contact the research team at gamzegul.altay@erdogan.edu.tr for enrollment information.

Where is the NCT07543029 trial being conducted?

This trial is being conducted at Rize, Turkey (Türkiye).

Who is sponsoring the NCT07543029 clinical trial?

NCT07543029 is sponsored by Recep Tayyip Erdogan University. The principal investigator is Gamzegül ALTAY, PhD at Recep Tayyip Erdogan University. The trial plans to enroll 112 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology